KRAS and lung adenocarcinoma: Notably, EGFR and KRAS mutations, which are common in lung adenocarcinoma, activate key signaling cascades such as MAPK/ERK and PI3K/AKT, which in turn modulate the expression of several oncogenic lncRNAs [32,33].